英菲格拉替尼(Infigratinib)各版本可以在哪里购买

Infigratinib is a targeted therapy for cholangiocarcinoma that targets specific gene mutations (FGFR2 fusions or rearrangements). As a kinase inhibitor, it provides a new treatment option for patients with unresectable locally advanced or metastatic cholangiocarcinoma.

Where can various versions of Infigratinib be purchased?

Currently, Infigratinib has not been approved for marketing by China’s National Medical Products Administration (NMPA), nor has it been included in China’s medical insurance reimbursement list. The US FDA approved its marketing in May 2021, with the trade name Truseltiq.

Online Platforms

Some compliant cross-border medical platforms can provide online purchases. When choosing a platform, you need to confirm the legality of its qualifications. It is recommended that the platform provide documents such as drug source certificates and quality inspection reports.

Participate in clinical trials

For eligible patients, participating in infigratinib-related clinical trials is a way to obtain regular treatment. Some domestic oncology hospitals may carry out relevant research, and patients can learn about recruitment information from their attending doctors. Successful enrollment usually results in free medication and professional medical monitoring.

How to store Infigratinib

Appropriate storage conditions are crucial to maintaining drug stability. Please strictly follow the following storage requirements.

Temperature and environmental control

Drugs should be stored in an environment between 20°C and 25°C, allowing short-term temperature fluctuations within the range of 15°C to 30°C. Avoid storing in places with humidity or large temperature changes such as bathrooms and kitchens. It is recommended to use special storage boxes for medicines when the temperature is high in summer.

Packaging and handling specifications

Keep the capsules in the original aluminum foil packaging until taking to prevent moisture. Check the appearance of the capsule before taking the medicine each time: the 100mg specification should have a white body/light orange cap, and the 25mg specification should have a white body/gray cap, both with corresponding black words printed on them. Do not use if the capsule is damaged, discolored, or the contents leak. Seal the medicine box immediately after taking the medicine.

The drug is valid for 24 months. The production date and expiration date are clearly marked on the packaging. Establish a medication record and use it within the specified period after opening the box. Expired medicines should be handed over to professional institutions for disposal and should not be discarded at will.

Usage and dosage of Infigratinib

Strictly follow the doctor’s instructions when taking medication, and consult the attending doctor in time if you feel unwell.

Standard medication regimen

The recommended dose is 125mg (1 tablet each of 100mg + 25mg), once a day, taken for 21 days and then stopped for 7 days, with a cycle of 28 days. It must be taken on an empty stomach, 1 hour before or 2 hours after meals. Swallow the whole tablet without chewing. Taking medication at a fixed time every day can help maintain stable blood drug concentrations.

Principles of dose adjustment

When adverse reactions occur, the dose needs to be gradually reduced, first to 100mg/day, second to 75mg/day, and third to 50mg/day.

The starting dose for patients with mild renal impairment or mild hepatic impairment is adjusted to 100 mg/day, and for patients with moderate hepatic impairment, the starting dose is 75 mg/day. Any dosage adjustments should be made under the guidance of a physician.

If you miss a dose for more than 4 hours or vomit after taking the medicine, there is no need to take a missed dose. Avoid combination with proton pump inhibitors. When H2 receptor antagonists must be combined, infigratinib should be taken 2 hours before or 10 hours after taking the H2 antagonist. Take antacids 2 hours apart.